Between 1982 and 2000, 172 patients with acute myelogenous leukaemia (AML) received
haematopoietic stem cell transplants (SCT) from related (n= 132) or unrelated (n= 40) …

To assess the place of allogeneic hematopoietic stem cell transplantation (HSCT) in the
advanced stage of acute myeloid leukemia (AML), we retrospectively analyzed 379 …

Background Outcomes for patients with acute myeloid leukaemia (AML) undergoing
allogeneic stem cell transplantation (allo‐SCT) have significantly improved in recent years …

We retrospectively assess the long-term outcome and determined prognostic factors
correlated with outcomes in adults with acute myeloid leukemia (AML) undergoing …

For patients with refractory acute myeloid leukemia (AML), allogeneic stem cell
transplantation (allo SCT) represents the only curative approach. We here analyzed the long …

For patients with acute myelogenous leukemia (AML) who are unable to secure an
acceptable HLA donor, the role of autologous stem cell transplantation (auto-SCT) has …

In this single-centre retrospective study, we analysed risk factors for nonrelapse long-term
morbidity and mortality in patients with acute myeloblastic leukaemia (AML) who had …

Allogeneic hematopoietic stem cell transplantation (HSCT) is the recommended therapy for
patients with relapsed acute myelogenous leukemia (AML), despite little evidence showing …

Introduction Despite substantial progress in the treatment of newly diagnosed AML, 20% to
40% of patients do not achieve remission with conventional induction chemotherapy. In …

Allogeneic hematopoietic stem-cell transplantation (allo-SCT) has an established role in the
treatment of patients with acute myeloid leukemia (AML). Although the majority of adult …